Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Statins and Diabetes: Despite Potential Link, Doctors Still Agree On Cholesterol-Lowering Effectiveness

XTALKS VITALS NEWS

Cholesterol

The article takes a strong stance on the issue, arguing that even if the unproven link was verified, the benefits of statins in preventing heart attacks and strokes far outweighs the minor risk of developing diabetes.

Share this!

January 19, 2017 | by Sarah Hand, M.Sc.

A commentary published in The American Journal of Medicine, has attempted to address the possible link between statins – a class of cholesterol-lowing drugs – and diabetes. The article takes a strong stance on the issue, arguing that even if the unproven link was verified, the benefits of statins in preventing heart attacks and strokes far outweighs the minor risk of developing diabetes.

“The totality of evidence clearly indicates that the more widespread and appropriate utilization of statins, as adjuncts, not alternatives to therapeutic lifestyle changes, will yield net benefits in the treatment and primary prevention of heart attacks and strokes, including among high, medium and low risk patients unwilling or unable to adopt therapeutic lifestyle changes,” said Dr. Charles H. Hennekens, professor at the Charles E. Schmidt College of Medicine at Florida Atlantic University, and one of three authors of the article.



In a related editorial, Dr. Joseph S. Alpert, editor-in-chief of the journal, as well as professor of medicine at the University of Arizona School of Medicine, agrees with the main points of the article and further emphasizes the challenges of treating and preventing heart disease. “There is no threshold for low density lipoprotein cholesterol below which there are no net benefits of statins either in the treatment or primary prevention of heart attacks and strokes,” said Alpert.

According to the authors, the possible risk of developing diabetes could prevent doctors from prescribing the drugs to patients who could benefit from treatment. Similarly, patients may refuse or cease treatment with statins if they are not properly informed of the benefits, potentially leading to an increase in preventable deaths due to heart attacks and strokes.

“These public health issues are especially alarming in primary prevention, particularly among women, for whom cardiovascular disease also is the leading cause of death, and for whom there is even more underutilization of statins than for men,” said Hennekens. In 2013, the American Heart Association published new guidelines for the use of statins which included broader use in both prevention and treatment of heart disease. Heart disease is responsible for around 600,000 US deaths per year, according to the Centers for Disease Control and Prevention (CDC).


Keywords: Statins, Diabetes, Cholesterol


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News


Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News


Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Electronic Informed Consent: 2017 Industry Survey Results


Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time


The Modernization of eCOA Technology for Clinical Trials


Developing a Biological Safety Evaluation


Copyright © 2016-2017 Honeycomb Worldwide Inc.